SCF ENCYCLOPEDIA ENTRY

DILATED CARDIOMYOPATHY (DCM)

SCF MYOCARDIAL-CONTRACTILITY & CARDIAC-SYNCHRONIZATION FAILURE DOSSIER

I. OFFICIAL DISEASE CLASSIFICATION

Dilated cardiomyopathy belongs to SCF Clinical Domains C9 (Cardiovascular Medicine), C2 (Cellular & Metabolic Medicine), C14 (Genetic & Developmental Medicine), C3 (Inflammation & Immunology), and C13 (Degenerative Systems Biology).

II. CLINICAL DEFINITION

Dilated cardiomyopathy is characterized by:

• Ventricular enlargement
• Reduced left ventricular ejection fraction (LVEF)
• Systolic dysfunction
• Progressive heart failure
• Arrhythmias
• Thromboembolic risk
• Sudden cardiac death risk

Primary affected systems:

• Cardiac myocytes
• Sarcomere networks
• Mitochondrial bioenergetic systems
• Cardiac conduction pathways
• Neurohormonal regulatory networks

Associated conditions:

• Heart failure
• Cardiomyopathy

III. MAJOR CLASSIFICATIONS

A. Idiopathic Dilated Cardiomyopathy

B. Familial Dilated Cardiomyopathy

C. Inflammatory Dilated Cardiomyopathy

D. Toxic Dilated Cardiomyopathy

E. Metabolic Dilated Cardiomyopathy

Associated condition:

• Viral myocarditis

IV. CORE SCF ETIOPATHOGENIC THESIS

Within the Synergistic Compatibility Framework (SCF), dilated cardiomyopathy represents a systems-level collapse of:

• Cardiac synchronization coherence
• Myocardial contractile equilibrium
• Bioenergetic cardiac harmonics
• Electrical-conduction stability
• Hemodynamic resilience

SCF interprets DCM as a decentralized cardiovascular communication disorder in which myocardial injury destabilizes synchronized contractile harmonics, leading to ventricular remodeling, pump failure, arrhythmias, and systemic circulatory dysfunction.

V. MYOCARDIAL FOUNDATION

Core Pathophysiologic Mechanisms

VI. MAJOR ETIOLOGIES & GENETIC CAUSES

Common Genetic Causes

Acquired Causes

Associated conditions:

• Peripartum cardiomyopathy
• Alcoholic cardiomyopathy

VII. SCF FAULT ARCHITECTURE

VIII. MULTI-OMICS PATHOGENESIS

A. Genomics

Associated pathways:

• Sarcomere biology
• Cytoskeletal architecture
• Calcium signaling
• Cardiac development networks

B. Transcriptomics

Dysregulated pathways:

• Fibrotic signaling
• Inflammatory activation
• Stress-response systems
• Hypertrophic remodeling pathways

C. Proteomics

Observed abnormalities:

• Sarcomeric proteins
• Extracellular matrix proteins
• Calcium-regulatory proteins
• Inflammatory mediators

D. Metabolomics

Key dysfunction:

• ATP depletion
• Fatty-acid oxidation impairment
• Lactate accumulation
• ROS excess
• Mitochondrial inefficiency

E. Epigenomics

• Remodeling-associated methylation changes
• Fibrosis-related chromatin alterations
• Stress-adaptive reprogramming

IX. SCF PATHOGENESIS FLOW

Stage 1 — Myocardial Injury

Cardiac structural integrity destabilizes.

Stage 2 — Contractile Dysfunction

Pump efficiency declines.

Stage 3 — Ventricular Remodeling

Chamber dilation develops.

Stage 4 — Neurohormonal Amplification

Compensatory mechanisms become maladaptive.

Stage 5 — Electrical Instability

Arrhythmias emerge.

Stage 6 — Heart Failure Progression

Chronic circulatory dysfunction stabilizes.

X. SYSTEMIC CONSEQUENCES

Associated conditions:

• Atrial fibrillation
• Ventricular tachycardia
• Sudden cardiac death

XI. RHENOVA INTERPRETATION

Project RHENOVA interprets DCM as a myocardial bioenergetic destabilization syndrome.

RHENOVA Dynamics

• Contractile amplification loops
• Mitochondrial respiratory failure
• Oxidative injury cascades
• Fibrotic remodeling progression
• Cardiac synchronization collapse

RHENOVA Biomarkers

XII. DBI INTERPRETATION

The SCF Decentralized Biological Intelligence framework interprets the cardiovascular system as a synchronized biological communication network coordinating:

• Hemodynamic flow
• Electrical conduction
• Tissue oxygen delivery
• Neurohormonal regulation
• Metabolic adaptation

DBI Failure Features

• Electrical signaling fragmentation
• Hemodynamic incoherence
• Neurohormonal instability
• Cardiac communication collapse

This transforms coordinated cardiovascular regulation into progressive pump failure.

XIII. CLINICAL MANIFESTATIONS

Cardiac Manifestations

• Dyspnea
• Fatigue
• Exercise intolerance
• Orthopnea
• Peripheral edema

Arrhythmic Manifestations

• Palpitations
• Syncope
• Sudden cardiac arrest

Hemodynamic Manifestations

• Hypotension
• Reduced cardiac output
• Cardiogenic shock (advanced disease)

Advanced Manifestations

• End-stage heart failure
• Ventricular arrhythmias
• Multiorgan hypoperfusion

XIV. DIAGNOSTICS

Diagnostic Hallmarks

Contractility-collapse principle:

Myocyte\ Dysfunction \Rightarrow Reduced\ Contractility

Remodeling relationship:

Contractile\ Failure \Rightarrow Ventricular\ Dilation

Heart-failure concept:

Ventricular\ Remodeling \Rightarrow Heart\ Failure

XV. SCF SYSTEMIC AXIS INVOLVEMENT

XVI. SCF TRINITY FRAMEWORK INTERPRETATION

SCF Trinity systems interpret dilated cardiomyopathy as a progressive collapse of synchronized myocardial harmonics.

XVII. STANDARD OF CARE

Guideline-Directed Medical Therapy

Examples:

• Sacubitril/valsartan
• Metoprolol succinate
• Carvedilol
• Spironolactone
• Dapagliflozin

Device Therapy

Associated devices:

• Implantable cardioverter-defibrillator
• Cardiac resynchronization therapy

Advanced Therapy

Associated condition:

• Left ventricular assist device

XVIII. SCF-PCR THERAPEUTIC ARCHITECTURE

A. Preventative (PCR-P)

Goals:

• Preserve myocardial synchronization
• Reduce oxidative injury
• Prevent remodeling progression

B. Curative (PCR-C)

Goals:

• Restore contractile signaling coherence
• Normalize calcium-handling pathways
• Reduce fibrotic amplification

C. Restorative (PCR-R)

Goals:

• Restore myocardial bioenergetics
• Normalize electrical communication coherence
• Reverse oxidative injury
• Rebuild cardiac synchronization harmonics

XIX. ETHNOBIOPROSPECTING TARGETS

Traditional Chinese Medicine

• Astragalus membranaceus
• Salvia miltiorrhiza

Ayurveda

• Terminalia arjuna
• Withania somnifera

Vietnamese Thuốc Nam

• Nelumbo nucifera
• Centella asiatica

XX. SCF API DISCOVERY TARGETS

High-Priority Molecular Targets

• Sarcomere-stabilization pathways
• Mitochondrial bioenergetic restoration systems
• Fibrosis-suppression pathways
• Calcium-handling optimization networks
• Cardiac regenerative signaling pathways
• Myocyte survival systems
• Electrical synchronization restoration platforms

XXI. VIRAGENESIS INTERSECTION

Dilated cardiomyopathy intersects with SCF Viragenesis models through:

• Viral myocarditis-mediated remodeling
• Chronic inflammatory amplification
• Mitochondrial adaptation stress
• Cardiomyocyte communication collapse

XXII. QUANTUM MEDICINE INTERPRETATION

Quantum Medicine within SCF interprets myocardial function as a synchronized bioinformational resonance network vulnerable to:

• Electrical decoherence
• Contractile oscillatory instability
• Hemodynamic synchronization collapse
• Bioenergetic destabilization

XXIII. CONSCIENCE MIND INTERSECTION

The Conscience Mind Framework intersects through:

• Chronic illness stress amplification
• HRV dysregulation
• Autonomic instability
• Chronobiological cardiovascular disruption

XXIV. SCF LAYMAN’S SUMMARY

Dilated cardiomyopathy is a disease in which the heart muscle becomes enlarged, weakened, and unable to pump blood effectively. The ventricles stretch and dilate, causing a progressive decline in cardiac output and often leading to heart failure, dangerous arrhythmias, stroke, or sudden cardiac death. Causes may include inherited genetic mutations, viral infections, autoimmune disease, alcohol toxicity, chemotherapy exposure, or metabolic disorders. SCF interprets dilated cardiomyopathy as a systems-level cardiac communication disorder involving myocardial injury, mitochondrial dysfunction, oxidative stress, maladaptive remodeling, and collapse of synchronized cardiovascular regulatory systems.

XXV. STRATEGIC RESEARCH PRIORITIES

1. Mitochondrial cardiac-restoration systems
2. Sarcomere-regeneration strategies
3. Anti-fibrotic therapeutics
4. AI-driven heart-failure forecasting
5. ROS-adaptive cardioprotective therapies
6. Cardiac synchronization systems
7. Regenerative myocardial signaling platforms

MASTER REGISTRY INDEX

SCF-DCM-0001 — Dilated Cardiomyopathy Master Registry

SCF-DCM-MYOCYTE-0002 — Myocardial Dysfunction Layer

SCF-DCM-CONTRACTILITY-0003 — Cardiac Synchronization Failure Layer

SCF-DCM-RHENOVA-0004 — Myocardial Bioenergetic Destabilization Layer

SCF-DCM-DBI-0005 — Cardiovascular Communication Failure Layer

SCF-DCM-PCR-0006 — Preventative–Curative–Restorative Layer